MRI-guided risk stratification for neoadjuvant immunotherapy in rectal cancer - Summary - MDSpire

MRI-guided risk stratification for neoadjuvant immunotherapy in rectal cancer

  • By

  • Jiali Zhang

  • Feng Tian

  • Yue Shang

  • Honghai Dai

  • Shuo Zhang

  • Bing Kang

  • Jiaxiang Xin

  • Ximing Wang

  • Changqing Jing

  • Cong Sun

  • May 29, 2026

  • 0 min

Share

Objective:

Add significance of the study in the context of existing literature.

Key Findings:
  • MRI-based assessment using mrEMVI, mrMRF, and tumor length ≥ 5 cm yielded a three-factor risk score predicting pCR with an AUC of 0.835.
  • In the MRI high-risk group (2–3 points), pCR rates were higher with nICRT (36.8%) than with nCRT (11.7%, P = 0.033).
  • In the low-risk group (0–1 points), the difference in pCR rates between nICRT and nCRT was not significant.
Interpretation:

Elaborate on clinical implications of findings.

Limitations:
  • Add detail on how biases may affect results.
Conclusion:

Emphasize the need for future research to validate findings.

Original Source(s)

MRI-guided risk stratification for neoadjuvant immunotherapy in rectal cancer

  • by Jiali Zhang, Feng Tian, Yue Shang, Honghai Dai, Shuo Zhang, Bing Kang, Jiaxiang Xin, Ximing Wang, Changqing Jing, Cong Sun

  • May 29, 2026

Related Content

Gastric-type endocervical adenocarcinoma with Peutz-Jeghers syndrome: a case report and literature review

Case Report: E-cadherin and Vimentin expression in advanced-stage pancreatic ductal adenocarcinoma tissue and circulating tumor cells: preliminary results from a pilot study

Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms